MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
Stocks in this Quantisnow insightHealth Care
Historical context for MAIA
Across the 23 sessions after earlier MAIA headlines, the stock closed higher 15 times and lower 7 times, with a median move of 5.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MAIA | SPY |
|---|---|---|---|
| Jun 4, 2026 | MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial | +4.9% | +0.4% |
| Jun 3, 2026 | MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion | +5.9% | -0.7% |
| Jun 2, 2026 | MAIA Biotechnology Announces Open Market Purchases by CEO and Director | +3.8% | +0.1% |
| Jun 1, 2026 | MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology | -6.5% | +0.3% |
| May 18, 2026 | Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) | +0.0% | -0.1% |
| Apr 16, 2026 | MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | -6.3% | +0.2% |
Quantisnow market dataAMEX
MAIA
MAIA Biotechnology Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2022
Get push alerts for MAIA
Full MAIA profile on Quantisnow Follow MAIA and get a push notification the moment its next story breaks.